Comparison and validation of bioactive flavonoids by reverse phase high performance liquid chromatography in crataegus species related to pharmaceutical crataegus product
By: Agiel, Najat
.
Contributor(s): Caleb, J.
Publisher: Mumbai Indian Journal of Pharmaceutical Science 2022Edition: Vol.84(2), Mar-Apr.Description: 444-452p.Subject(s): PHARMACEUTICSOnline resources: Click here
In:
Indian journal of pharmaceutical sciencesSummary: The use of Crataegus species for the treatment of cardiovascular ailments is widely distributed. Even then
only a few species are included in the Pharmacopoeias. In this study bioactive flavonoids of Crataegus
azarolus and Crataegus pallasii were identified and quantified in comparison with the well-known
pharmaceutical product of Crataegus; Crataegutt ® Tropfen using reverse phase-high performance liquid
chromatography. The method developed is simple, fast, reliable and sensitive. In an attempt to reduce
matrix effect prior to high performance liquid chromatography analysis, a novel approach is proposed
as an efficient simple clean-up technique termed “indirect-dispersive liquid-liquid microextraction”.
Validation parameters of the method were calculated as follows: Limit of detection ranged from 0.4 to
3.4 mg/g and limit of quantitation from 1.3 to 11.3 mg/g, intraday and interday precision expressed as
percentage relative standard deviation ranged from 1.0 to 2.8 and 1.5 to 4.3, respectively and r2 values were
above 0.9950 for all analytes. The relative recovery of all analytes was more than 98 %. Four predominate
peaks were identified using certified standards as Vitexin 2''-O-rhamnoside, rutin, vitexin and hyperoside,
with mass concentration (% w/w) in Crataegus azarolus as 4.4 %, 2.9 %, 1.7 % and 4.4 %, in Crataegus
pallasii as 4.4 %, 2.6 %, 1.4 % and 4.8 % and in Crataegutt® Tropfen as 1.6 %, 1.0 %, 0.6 % and
0.4 % respectively. Thus, the values met the criteria of the United States Pharmacopeia and the European
Pharmacopeia monographs. Our investigations postulate that Crataegus azarolus and Crataegus pallasii
could be a good source for the production of Crataegus phytomediciness.
| Item type | Current location | Call number | Status | Date due | Barcode | Item holds |
|---|---|---|---|---|---|---|
Articles Abstract Database
|
School of Pharmacy Archieval Section | Not for loan | 2022-2186 |
The use of Crataegus species for the treatment of cardiovascular ailments is widely distributed. Even then
only a few species are included in the Pharmacopoeias. In this study bioactive flavonoids of Crataegus
azarolus and Crataegus pallasii were identified and quantified in comparison with the well-known
pharmaceutical product of Crataegus; Crataegutt ® Tropfen using reverse phase-high performance liquid
chromatography. The method developed is simple, fast, reliable and sensitive. In an attempt to reduce
matrix effect prior to high performance liquid chromatography analysis, a novel approach is proposed
as an efficient simple clean-up technique termed “indirect-dispersive liquid-liquid microextraction”.
Validation parameters of the method were calculated as follows: Limit of detection ranged from 0.4 to
3.4 mg/g and limit of quantitation from 1.3 to 11.3 mg/g, intraday and interday precision expressed as
percentage relative standard deviation ranged from 1.0 to 2.8 and 1.5 to 4.3, respectively and r2 values were
above 0.9950 for all analytes. The relative recovery of all analytes was more than 98 %. Four predominate
peaks were identified using certified standards as Vitexin 2''-O-rhamnoside, rutin, vitexin and hyperoside,
with mass concentration (% w/w) in Crataegus azarolus as 4.4 %, 2.9 %, 1.7 % and 4.4 %, in Crataegus
pallasii as 4.4 %, 2.6 %, 1.4 % and 4.8 % and in Crataegutt® Tropfen as 1.6 %, 1.0 %, 0.6 % and
0.4 % respectively. Thus, the values met the criteria of the United States Pharmacopeia and the European
Pharmacopeia monographs. Our investigations postulate that Crataegus azarolus and Crataegus pallasii
could be a good source for the production of Crataegus phytomediciness.
Click on an image to view it in the image viewer
There are no comments for this item.